Major News/Events :

Future Waves Design Win -- May 2007

Key Development Milestone -- Feb 2007

Toumaz Wins Oracle Award -- Dec 2006


Nanoscience Inc, is a specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector.

Web Sites of companies in which NAN has an interest :

http://www.toumaz.com/

http://www.f-waves.com/

http://www.appliedsensor.com

http://www.xrt.com.au/

Comments over at AFN of it possibly being "Medtronic".


I suggest reading thos post from AFN, copied below :


"""""""""spekky - 28 Nov'07 - 09:44 - 247 of 268

If your one of those people who only do the occasional bit of research on your chosen share,then this should be the one its a MUST READ.

http://www.raeng.org.uk/events/pdf/Welcome_Trust_transcript.pdf

Pages 25-38 is a transcript of a speech on 29/10/07 at the royal academy of engineering by prof.Chris Toumazou.

AMAZING STUFF (even i can understand it).Look particularly at those companies he mentions."""""""""""

PP... thanks for reply ..... would certainly be interesting if it was ?Medtronic:

"Medtronic is the global leader in medical technology ...... Revenue for the year ended April 27, 2007: $12.3 billion...... New York Stock Exchange ticker: MDT."

From RNS today:

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions from within the growing nanotechnology sector, is
pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited
(`Toumaz') has been granted its core patent surrounding the AMx (Advanced
Mixed Signal) technology in the key jurisdiction of Australia. The new patent,
already granted in the UK and the US, covers the core technology that enables
the Sensium platform to operate using orders of magnitude lower power than
existing semi-conductor solutions, leading to a dramatic reduction in battery
size for portable devices and extended operating times.

Full details at:
RNS re Patent Grant

Every patent helps..... Let's see if NAN will get a mention in the financial press in a couple of weeks time as one of the stock picks for 2008......

Anyone with a theory on what looks like a huge rollover trade?

No theory personally. But someone on another board had the opinion that it was a transfer between institutions via a broker. Perhaps SAAD were involved. If so, an RNS will follow.

http://www.investegate.co.uk/Article.aspx?id=20080124070000P7544

Nanoscience Inc.

(`The Group')

Toumaz Technology Awarded ISO 13485 Medical Device Quality

Management Certification for Sensium Wireless Body

Monitoring Platform

Toumaz's commitment to the highest quality management standard required for
medical device manufacture recognised by independent accrediting body

Nanoscience Inc, the specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector,
is pleased to announce that its wholly owned subsidiary Toumaz Technology
Limited (`Toumaz') has received ISO 13485:2003 certification for its quality
management system. ISO 13485 is the regulatory standard for the international
medical industry and is closely related to ISO 9000. Toumaz (a leading provider
of ultra-low power wireless infrastructure for body monitoring solutions) was
assessed and certified as meeting the requirements of this strategically
significant standard by independent body SGS, the world's leading verification
and certification body.

ISO 13485 is a regulatory requirement in a number of international markets for
the manufacture of medical devices, and forms the cornerstone for the CE
certification of medical products in the EU. Meeting the ISO quality management
standard is a crucial milestone in the ongoing commercialisation of Sensium,
Toumaz's breakthrough ultra-low power wireless platform for the development of
non-intrusive body monitors for healthcare and lifestyle markets. In November
2007, Toumaz took the top honours in the Electronics category of the
prestigious Innovation in Engineering Awards - given by The Institution of
Engineering and Technology - in recognition of the groundbreaking innovation of
the Sensium as an enabling technology for highly valuable medical applications.

Keith Errey, COO, Toumaz, commented:

"We are delighted that Toumaz has been awarded the important ISO 13485
certification, which demonstrates our absolute commitment to quality throughout
the product cycle including the manufacture of medical devices, and which will
offer significant benefits to our customers."

The unique combination of ultra-low power wireless and signal processing in one
small System-on-Chip (SOC) allows the economies of scale of the semiconductor
industry to be harnessed to provide highly functional, robust, low cost,
disposable and non-intrusive monitors for a wide range of healthcare
applications.

The Sensium sensor interface and transceiver platform enables real-time,
intelligent, ultra-low power wireless monitoring of multiple vital signs - such
as ECG, heart rate, body temperature, respiration and physical activity (via a
3-axis accelerometer) - and is currently being developed in both disposable and
non-disposable body monitoring products.



- Ends -

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless
infrastructure for body monitoring solutions.

Toumaz's ultra low-power smart sensor interface and transceiver platform - the
Sensium - enables non-intrusive, real-time wireless monitoring of multiple
vital signs for a wide range of healthcare and lifestyle management
applications. Based on Toumaz's patented ultra-low power Advanced Mixed Signal
(AMx) technology, the Sensium provides the enabling technology to connect the
mobile individual to healthcare providers - simply, affordably and
unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active
monitoring and improved quality of care. For patients, it delivers new
opportunities for lifestyle-compatible, personalised healthcare, as well as
better therapeutic outcomes.

Nanoscience Inc
11 April 2008

Nanoscience Inc.
('Nanoscience' or the 'Group')

Toumaz Technology As Part of Consortium That Wins 7.1 million European
Community Grant

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased to announce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'), is part of a major collaborative research project that has been awarded a 7.1 million grant to fund the development of a portable blood glucose predictor system for diabetes patients.

The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is a
unique personalised blood glucose prediction tool that allows patients at any
time to actively and accurately predict their short-term blood glucose outlook
by the analysis of data retrieved from glucose measurements, insulin delivery
data and specific patient parameters, which will be captured by non-intrusive
body-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform.

The grant award, made under the Seventh Framework Programme (FP7) of the
European Community, will fund the four-year research and development project
into the DIAdvisorTM system. The large-scale project is being coordinated by
Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a
consortium of 13 medical, industrial and academic partners, including the
European Division of the International Diabetes Federation.

Toumaz's role in the project will be to implement the DIAdvisorTM hardware and
software platform, leverage the SensiumTM intelligent data acquisition platform
and networking infrastructure to enable multiple vital signs measurements from
non-intrusive body-worn monitors to be taken and merged with manually entered '
spot' measurements (such as food intake), providing the key data for the
creation of physiological mathematical modeling, control and prediction
algorithms. The resulting analysis and prediction information will then be able
to be wirelessly transmitted to a healthcare provider advisory service, with
recommended action and treatment advice presented to the patient via a handheld
mobile device such as a Personal Digital Assistant (PDA).

First stage data gathering and clinical trials are planned to start in August
2008, with initial data expected by the end of the year.

Dr Alison Burdett, Director of Technology for Toumaz commented:

'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in the
hands of patients for the first time, empowering them in their own healthcare
management and significantly reducing the likelihood of serious complications
and recurrent hospitalisation due to poor glucose control. For healthcare
providers, DIAdvisorTM will have a significant positive impact on cost reduction for the treatment of diabetes.'

Guy Spelman CEO of Nanoscience commented:

'This is further good news from our investment in Toumaz and its development of
the SensiumTM platform. Recognition of the growing importance of the SensiumTM
platform in more sectors in the field of medicine provides further evidence of
its versatility and increasing acceptance across global leaders and government
bodies.'


- Ends -